Flagship Ventures

Type: Company
Name: Flagship Ventures
First reported Apr 15 2014 - Updated Apr 15 2014 - 1 reports

Renaissance commits $4m to Plymouth Venture Partners III

Michigan-based fund of funds Renaissance Venture Capital Fund has made a $4m commitment to local VC firm Plymouth Ventures ‘ third fund.The firm invests in growth stage companies in the Great Lakes region.Plymouth Venture Partners III has a target of ... [Published AltAssets.net - Apr 15 2014]
First reported Apr 03 2014 - Updated Apr 03 2014 - 1 reports

Celgene pays VCs $47M to up its stake in Acceleron's pipeline

The dealmakers at Celgene like to get really, really close to their biotech partners. And nothing demonstrates the sincerity of their interest in new technologies better than the acquisition of a nice big chunk of equity.That strategy is paying off handsomely ... [Published FierceBiotech - Apr 03 2014]
First reported Apr 02 2014 - Updated Apr 02 2014 - 1 reports

ACCELERON PHARMA INC FILES (8-K) Disclosing Other Events

Item 8.01 Other Events.Celgene Corporation has entered into Stock Purchase Agreementsindividually with five current stockholders of the Company: AdvancedTechnology Ventures, Flagship Ventures, Polaris Venture Partners,Venrock, and Alkermes, Inc., all ... [Published HispanicBusiness.com - Apr 02 2014]
First reported Apr 02 2014 - Updated Apr 02 2014 - 1 reports

Polaris Partners promotes Bitterman to partner after 10 years at firm

Technology and healthcare-focused investment firm Polaris Partners has promoted Kevin Bitterman to partner after a decade at the firm. Bitterman, who deals with healthcare investing for the firm, was co-founder of Sirtris Pharmaceuticals and Genocea Biosciences, ... [Published AltAssets.net - Apr 02 2014]
First reported Apr 02 2014 - Updated Apr 02 2014 - 1 reports

CELGENE : Agrees to Acquire 1.1 Million Acceleron Pharma Shares

By Tess StynesCelgene Corp. ( >> Celgene Corporation ) agreed to acquire 1.1 million shares of Acceleron Pharma Inc. ( >> Acceleron Pharma Inc ) from selling shareholders for about $47 million, which will raise the biopharmaceutical giant's ... [Published 4 Traders - Apr 02 2014]
First reported Mar 27 2014 - Updated Mar 27 2014 - 1 reports

What’s Hot in Boston Biotech: Here’s the Agenda for April 16

There are plenty of reasons Wall Street is jittery that a biotech bubble is about to pop. But this bull market formed for a reason: innovative new science is sprouting up all over the biotech world, and some of it is on the verge of potentially delivering ... [Published Xconomy - Mar 27 2014]
First reported Mar 12 2014 - Updated Mar 12 2014 - 1 reports

Seres Health CEO, Flagship partner named Young Global Leader

David Berry, a partner at Flagship Ventures who co-founded such companies as Seres Health and Eleven Biotherapeutics, has been named a 2014 Young Global Leader by the World Economic Forum.Berry, 35, shares the designation with 214 other people around ... [Published Boston Business Journal - Mar 12 2014]
First reported Mar 11 2014 - Updated Mar 12 2014 - 1 reports

Flagship Ventures Partner David Berry Named a 2014 Young Global Leader by the World Economic Forum

CAMBRIDGE, Mass., March 11, 2014 /PRNewswire/ -- Flagship Ventures, a leading venture capital and venture creation firm focused on healthcare and sustainability, today announced that Dr. David Berry, Partner at Flagship Ventures, has been selected by ... [Published PR Newswire: Financial Services - Mar 11 2014]
First reported Mar 10 2014 - Updated Mar 10 2014 - 1 reports

Fracking: Adressing the Water-Energy Nexus

Home › UMass Boston News › Events › Event Date:  March 31, 2014 - 5:30 p.m.Event Type:  Open to public | Location:  Ryan Lounge, 3rd Floor, MicCormack HallFracking for natural gas is extremely controversial. It has dramatically reduced the price of gas ... [Published University of Massachusetts Boston - Mar 10 2014]
First reported Feb 17 2014 - Updated Feb 17 2014 - 1 reports

Pronutria announces launch of two clinical trials

Pronutria has announced the beginning of two clinical trials evaluating its lead ProNutrein product candidates.The company is utilizing its ProNutrein discovery platform to identify and develop protein pharmaconutrients, protein nutrients identified in ... [Published Pharmaceutical Business Review - Feb 17 2014]
First reported Feb 14 2014 - Updated Feb 14 2014 - 1 reports

Flagship leads $12.25 mln round for Pronutria

Pronutria has raised $12.25 million in Series B financing. Flagship Ventures led the round. Based in Cambridge, Mass., Pronutria is a maker of medical foods and nutritional supplements. PRESS RELEASE CAMBRIDGE, Mass., Feb. 13, 2014 /PRNewswire/ ... [Published PE Hub Blog - Feb 14 2014]
First reported Feb 05 2014 - Updated Feb 05 2014 - 3 reports

So that’s what happened to the VC-backed biofuel startup LS9 (it’s not pretty)

Biofuel startup LS9 has been sold for $40 million to biodiesel maker Renewable Energy Group, reports MIT Tech Review . But before you congratulate them, note that LS9 raised $81 million over nine years, and still hadn’t reached a point where it was ... [Published GigaOM - Feb 05 2014]
Entities: LS9 Inc, Biofuels, Startup

Quotes

...3 billion in capital," said Founder David J Brophy. "The exposure to investment capital is just one phenomenal byproduct of presenting. In addition, the Symposium serves as a great venue for networking with members of the innovation ecosystem and provides participating companies with hands-on mentoring and coaching from our team of industry experts."
"We are excited to collaborate with AstraZeneca, a leading global biopharmaceutical company committed to developing innovative cancer medicines,” said Purnanand Sarma, PhD, President and CEO, TARIS Biomedical®. “Through this collaboration, TARIS will have the opportunity to evaluate its proprietary bladder delivery platform in an oncology setting, potentially providing multiple novel product candidates to treat bladder cancer. Treatment options in bladder cancer are poor, and we believe our technology has the potential to revolutionize the treatment in this area. Collaboration with AstraZeneca is a validation of the potential of our technology, and leverages TARIS’s know-how in bladder delivery and bladder cancer, one the several therapeutic areas of focus for the company.”"
Martina Larkin, senior director and head of the Network of Global Agenda Councils, said: "2014 will be a crucial year for these technologies. Close cooperation between governments, industry and academia is essential to harness their potential." Brain-computer interfaces: It is already possible to type just by monitoring the electrical activity of your brain, but as the technology advances, it...
..."This makes the share structure very easy," Barbut wrote. "For employees, common stockstock options (sweat equity), and for investors, preferred shares, all [have] the same liquidation rights and thus comply with Swiss statutes, which are very stringent on equal treatment for ALL shareholders."   CEO since 2000, Barbut said when the Series B started, he didn't expect it to carry on this long...

More Content

All (35) | News (23) | Reports (0) | Blogs (11) | Audio/Video (0) | Fact Sheets (0) | Press Releases (1)
sort by: Date | Relevance
Renaissance commits $4m to Plymouth Venture Par... [Published AltAssets.net - Apr 15 2014]
Celgene pays VCs $47M to up its stake in Accele... [Published FierceBiotech - Apr 03 2014]
Polaris Partners promotes Bitterman to partner ... [Published AltAssets.net - Apr 02 2014]
CELGENE : Agrees to Acquire 1.1 Million Acceler... [Published 4 Traders - Apr 02 2014]
ACCELERON PHARMA INC FILES (8-K) Disclosing Oth... [Published HispanicBusiness.com - Apr 02 2014]
What’s Hot in Boston Biotech: Here’s the Agenda... [Published Xconomy - Mar 27 2014]
Deadline Approaches for Presenting Companies at... [Published I Stock Analyst - Mar 26 2014]
Once Seen As Too Scary, Editing People's Genes ... [Published Forbes.com - Mar 26 2014]
Seres Health to Present at 21st Annual BioCentu... [Published Digital Journal - Mar 25 2014]
TARIS® Biomedical Enters Research Collaboration... [Published AstraZeneca - Mar 19 2014]
Eleven Biotherapeutics Presents Positive Clinic... [Published Flagship Ventures - Mar 18 2014]
Seres Health CEO, Flagship partner named Young ... [Published Boston Business Journal - Mar 12 2014]
Flagship Ventures Partner David Berry Named a 2... [Published PR Newswire: Financial Services - Mar 11 2014]
Fracking: Adressing the Water-Energy Nexus [Published University of Massachusetts Boston - Mar 10 2014]
Top ten emerging technologies which could shape... [Published Telegraph - Feb 26 2014]
Financings of the Fortnight And the Neverending... [Published The IN VIVO Blog - Feb 21 2014]
Pronutria announces launch of two clinical trials [Published Pharmaceutical Business Review - Feb 17 2014]
Flagship leads $12.25 mln round for Pronutria [Published PE Hub Blog - Feb 14 2014]
Top Insider Trades: THRX AYR SFLY JEC [Published The Street Latest - Feb 14 2014]
VC-backed Eleven Biotherapeutics raises $50 mln... [Published PE Hub Blog - Feb 07 2014]
These Days, You Can't Spell Financings Of The F... [Published The IN VIVO Blog - Feb 07 2014]
So that’s what happened to the VC-backed biofue... [Published GigaOM - Feb 05 2014]
So that’s what happened to the VC-backed biofue... [Published GigaOM Network - Feb 05 2014]
So that’s what happened to the VC-backed biofue... [Published Earth2Tech - Feb 05 2014]
WERF selects four new board members [Published Water Technology Online - Jan 30 2014]
Blend Therapeutics Appoints Richard Wooster Ph.... [Published BioPortfolio - Jan 06 2014]
Dr. Nathanael Gray a Syros Pharmaceuticals Scie... [Published BioPortfolio - Dec 16 2013]
Editas Medicine secures Series A financing [Published Pharmaceutical Business Review - Nov 26 2013]
Genome engineering startup gets $43M to cut out... [Published GigaOM Network - Nov 25 2013]
Genome engineering startup gets $43M to cut out... [Published GigaOM Network - Nov 25 2013]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Flagship Ventures Partner David Berry Named a 2... [Published PR Newswire: Financial Services - Mar 11 2014]
CAMBRIDGE, Mass., March 11, 2014 /PRNewswire/ -- Flagship Ventures, a leading venture capital and venture creation firm focused on healthcare and sustainability, today announced that Dr. David Berry, Partner at Flagship Ventures, has been selected by ...
Financings of the Fortnight And the Neverending... [Published The IN VIVO Blog - Feb 21 2014]
Somewhere out there, perhaps, is the end of NovImmune's Series B round.More than a year ago, our friends at START-UP examined the fates of biotechs that had reeled in huge private financing rounds. Giant biotech venture rounds are back with a buzz ...
Flagship leads $12.25 mln round for Pronutria [Published PE Hub Blog - Feb 14 2014]
Pronutria has raised $12.25 million in Series B financing. Flagship Ventures led the round. Based in Cambridge, Mass., Pronutria is a maker of medical foods and nutritional supplements. PRESS RELEASE CAMBRIDGE, Mass., Feb. 13, 2014 /PRNewswire/ ...
VC-backed Eleven Biotherapeutics raises $50 mln... [Published PE Hub Blog - Feb 07 2014]
Biopharmaceutical company Eleven Biotherapeutics raised $50 million in its IPO after having priced its offering of 5 million shares at $10 per share. The stock began trading Thursday on the NASDAQ under the ticker symbol “EBIO.” Citigroup, Cowen ...
These Days, You Can't Spell Financings Of The F... [Published The IN VIVO Blog - Feb 07 2014]
It turns out a lot of the words that contain the letters "IPO" are biomedical words: Pluripotent. Liposomal. Adiposis. Gallipot . And it turns out a lot of biomedical companies have IPO in them, too. Since we last met 14 days ago , dear reader, ...
1 2 3

Press Releases

sort by: Date | Relevance
Flagship VentureLabs™ Launches Pronutria to Pre... [Published PR Newswire - Oct 22 2013]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.